Fennec Pharmaceuticals Inc. (TSE:FRX) Senior Officer Buys C$54,248.88 in Stock

Fennec Pharmaceuticals Inc. (TSE:FRX) Senior Officer Robert Christopher Andrade purchased 15,816 shares of the stock in a transaction dated Monday, November 18th. The shares were acquired at an average cost of C$3.43 per share, for a total transaction of C$54,248.88.

Fennec Pharmaceuticals Stock Performance

Shares of FRX opened at C$7.35 on Friday. Fennec Pharmaceuticals Inc. has a one year low of C$5.65 and a one year high of C$15.43. The business has a fifty day moving average of C$6.39 and a 200 day moving average of C$7.98. The company has a debt-to-equity ratio of 1,040.68, a current ratio of 8.02 and a quick ratio of 10.17. The firm has a market capitalization of C$201.10 million, a P/E ratio of 65.90 and a beta of 0.25.

Analysts Set New Price Targets

Separately, Stephens raised shares of Fennec Pharmaceuticals to a “strong-buy” rating in a report on Monday, November 18th.

About Fennec Pharmaceuticals

Fennec Pharmaceuticals Inc operates as a biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. It sells its products through regional pediatric oncology specialists and medical science liaisons.